dr. bible on impact of lenvatinib on treatment landscape of dtc
Published 8 years ago • 561 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
0:48
dr. cabanillas on lenvatinib as first-line therapy for patients with dtc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
0:59
dr. martins on managing toxicities associated with lenvatinib in dtc
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
1:05
dr. brose on unique elements of the lenvatinib trial
-
6:47
lenvatinib: new kid on the block
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
1:39
dr. bastholt on lenvatinib in thyroid cancer
-
2:07
dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
-
1:10
dr. marcia brose on lenvatinib in differentiated thyroid cancer
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
3:56
lenvatinib: exploring dose reductions and interruptions
-
2:51
practical experience with lenvatinib/everolimus in rcc
-
6:42
the role of lenvatinib in advanced rcc
-
7:03
lenvatinib breakthrough designation, new drug applications for nsclc and sts, and more
-
1:52
dr. bekaii-saab discusses the fda approval of lenvatinib in hcc
-
9:47
sorafenib in advanced dtc
-
2:13
dr. hutson on lenvatinib/everolimus combo in rcc
-
8:55
implication of upfront lenvatinib in hcc